We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
Read MoreHide Full Article
Key Takeaways
GRAIL expects an early Q1 2027 FDA decision on Galleri, with approval opening a path to reimbursement.
GRAIL lowered 2026 Galleri revenue growth guidance to 17%-21% as average selling prices declined.
Galleri's September promotion cut its average price to about $660 as adjusted gross margin fell to 42%.
GRAIL, Inc. (GRAL - Free Report) is prioritizing broader Galleri adoption ahead of a potentially pivotal U.S. regulatory decision, even as lower selling prices weigh on growth and margins.
On its third-quarter 2026 earnings call, executives described FDA approval as a gateway to reimbursement while addressing softer demand, increased competition and a more measured sales outlook.
GRAL Targets an Early 2027 FDA Decision
CEO Joshua Ofman said that the FDA's advisory committee voted favorably on Galleri in September. The company anticipates a final decision by early first quarter 2027 following its January premarket approval submission.
During questions from TD Cowen, chief scientific officer Harpal Kumar said that discussions with the agency remain active, including label negotiations. He stressed that the FDA has not provided a specific decision date.
In response to Guggenheim Securities, Ofman said that the agency has not raised follow-up questions about documented shared decision-making, an issue panelists discussed. Management expects the intended use to reflect evidence submitted for adults 50 and older.
GRAIL Resets Sales Growth Expectations
Chief financial officer Aaron Freidin updated 2026 Galleri sales revenue growth guidance to 17-21%, citing lower average selling prices. The company retained a cash burn ceiling of $300 million for the year.
Third-quarter revenues rose 4% to $37.5 million, below the $43.10 million Zacks Consensus Estimate. The reported loss of $2.21 per share was narrower than the expected loss of $2.78 per share.
Screening revenues grew 14% despite a 24% increase in test volume to more than 56,000. Freidin said the divergence reflected pricing pressure as the company favored market penetration over near-term margin optimization.
GRAL Uses Promotions to Bolster Test Demand
Freidin said that September's promotion lowered Galleri's average selling price to approximately $660. He views price as a significant barrier in the self-pay market and expects discounts to stimulate demand.
Questioned by Guggenheim Securities about price elasticity, Freidin indicated current pricing should broadly carry through year-end but did not provide a 2027 pricing framework. The promotion will also help inform interim pricing strategy.
Adjusted gross margin fell to 42% from 55% a year earlier. Freidin flagged the resumption of an Illumina royalty in late December, which will affect gross margins in the first quarter of 2027.
GRAIL Highlights Clinical Evidence Amid Scrutiny
Ofman highlighted NHS-Galleri and PATHFINDER-2 publications as support for the test's clinical positioning. Management cited fourfold to 6.5-fold increases in cancer detection when Galleri supplemented standard screening.
The NHS-Galleri trial did not show a combined decline in Stage III and IV cancers. However, it demonstrated a greater than 20% reduction in Stage IV diagnoses among 12 prespecified aggressive cancers.
Ofman acknowledged that negative headlines about the NHS data weighed on demand, while Chief Growth Officer Andrew Partridge said the publications helped strengthen conversations with prescribing physicians.
GRAL Maps a Path to Wider Coverage
Partridge said that the first Epic integration went live late in the quarter, with more health systems lined up through year-end and into 2027. The provider sales force expanded from 90 to 120 in June.
Responding to Canaccord Genuity, Partridge said that FDA approval could deepen health-system adoption and payer discussions. Ofman added that GRAIL intends to seek a CMS national coverage analysis once approval is secured.
During Mizuho's questions, Freidin said that FDA authorization would produce a smaller growth inflection than reimbursement or screening guidelines. Management is also pursuing commercial payers and Medicare Advantage plans.
GRAIL Keeps Reimbursement in View
Ofman described near-term priorities as securing regulatory clearance, expanding the reimbursement evidence base and building repeat test demand. Competition remains a commercial challenge as Galleri operates predominantly in a self-pay market.
Freidin said that GRAIL ended September with $788.7 million in cash, cash equivalents and short-term marketable securities, providing runway into 2029. The company is preparing for higher commercial investment if approval arrives.
GRAL's Zacks Rank and Style Scores
GRAL carries a Zacks Rank #4 (Sell) at present, associated with unfavorable earnings estimate revisions and weaker near-term performance prospects. Its Momentum Score of A indicates strong price-trend characteristics, but its Value Score of F signals limited value appeal.
The Growth Score of C indicates a middling growth profile, while the VGM Score of D reflects a weak combined value, growth and momentum profile. The unfavorable Zacks Rank tempers the positive momentum signal and can change as analysts revise estimates following the reported quarter.
View the Zacks #1 Rank List
Image: Bigstock
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
Key Takeaways
GRAIL, Inc. (GRAL - Free Report) is prioritizing broader Galleri adoption ahead of a potentially pivotal U.S. regulatory decision, even as lower selling prices weigh on growth and margins.
On its third-quarter 2026 earnings call, executives described FDA approval as a gateway to reimbursement while addressing softer demand, increased competition and a more measured sales outlook.
GRAL Targets an Early 2027 FDA Decision
CEO Joshua Ofman said that the FDA's advisory committee voted favorably on Galleri in September. The company anticipates a final decision by early first quarter 2027 following its January premarket approval submission.
During questions from TD Cowen, chief scientific officer Harpal Kumar said that discussions with the agency remain active, including label negotiations. He stressed that the FDA has not provided a specific decision date.
In response to Guggenheim Securities, Ofman said that the agency has not raised follow-up questions about documented shared decision-making, an issue panelists discussed. Management expects the intended use to reflect evidence submitted for adults 50 and older.
GRAIL Resets Sales Growth Expectations
Chief financial officer Aaron Freidin updated 2026 Galleri sales revenue growth guidance to 17-21%, citing lower average selling prices. The company retained a cash burn ceiling of $300 million for the year.
Third-quarter revenues rose 4% to $37.5 million, below the $43.10 million Zacks Consensus Estimate. The reported loss of $2.21 per share was narrower than the expected loss of $2.78 per share.
GRAIL, Inc. Price, Consensus and EPS Surprise
GRAIL, Inc. price-consensus-eps-surprise-chart | GRAIL, Inc. Quote
Screening revenues grew 14% despite a 24% increase in test volume to more than 56,000. Freidin said the divergence reflected pricing pressure as the company favored market penetration over near-term margin optimization.
GRAL Uses Promotions to Bolster Test Demand
Freidin said that September's promotion lowered Galleri's average selling price to approximately $660. He views price as a significant barrier in the self-pay market and expects discounts to stimulate demand.
Questioned by Guggenheim Securities about price elasticity, Freidin indicated current pricing should broadly carry through year-end but did not provide a 2027 pricing framework. The promotion will also help inform interim pricing strategy.
Adjusted gross margin fell to 42% from 55% a year earlier. Freidin flagged the resumption of an Illumina royalty in late December, which will affect gross margins in the first quarter of 2027.
GRAIL Highlights Clinical Evidence Amid Scrutiny
Ofman highlighted NHS-Galleri and PATHFINDER-2 publications as support for the test's clinical positioning. Management cited fourfold to 6.5-fold increases in cancer detection when Galleri supplemented standard screening.
The NHS-Galleri trial did not show a combined decline in Stage III and IV cancers. However, it demonstrated a greater than 20% reduction in Stage IV diagnoses among 12 prespecified aggressive cancers.
Ofman acknowledged that negative headlines about the NHS data weighed on demand, while Chief Growth Officer Andrew Partridge said the publications helped strengthen conversations with prescribing physicians.
GRAL Maps a Path to Wider Coverage
Partridge said that the first Epic integration went live late in the quarter, with more health systems lined up through year-end and into 2027. The provider sales force expanded from 90 to 120 in June.
Responding to Canaccord Genuity, Partridge said that FDA approval could deepen health-system adoption and payer discussions. Ofman added that GRAIL intends to seek a CMS national coverage analysis once approval is secured.
During Mizuho's questions, Freidin said that FDA authorization would produce a smaller growth inflection than reimbursement or screening guidelines. Management is also pursuing commercial payers and Medicare Advantage plans.
GRAIL Keeps Reimbursement in View
Ofman described near-term priorities as securing regulatory clearance, expanding the reimbursement evidence base and building repeat test demand. Competition remains a commercial challenge as Galleri operates predominantly in a self-pay market.
Freidin said that GRAIL ended September with $788.7 million in cash, cash equivalents and short-term marketable securities, providing runway into 2029. The company is preparing for higher commercial investment if approval arrives.
GRAL's Zacks Rank and Style Scores
GRAL carries a Zacks Rank #4 (Sell) at present, associated with unfavorable earnings estimate revisions and weaker near-term performance prospects. Its Momentum Score of A indicates strong price-trend characteristics, but its Value Score of F signals limited value appeal.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Growth Score of C indicates a middling growth profile, while the VGM Score of D reflects a weak combined value, growth and momentum profile. The unfavorable Zacks Rank tempers the positive momentum signal and can change as analysts revise estimates following the reported quarter.